Consumer Healthcare

Our brands relate to 4 therapeutic areas, with a specific expertise in gastroenterology.

Our products

  • All products
  • Food Supplements
  • Gastro-intestinal Conditions
  • Medical Devices
  • Other Conditions
Gastro-intestinal Conditions

smecta® (Diosmectite)

smecta® is an oral formulation of pharmaceutical clay indicated in the treatment of acute diarrhea in both adults and children, and the symptomatic treatment of digestive pain and chronic diarrhea in adults. The active substance in smecta® is diosmectite, a natural clay processed and purified for therapeutic use.

As of 31 December 2017, smecta® and other products in its range (flavors, OTC) are in about 60 countries. In 2017, smecta® sales represented 6.0% of total Ipsen sales, of which 75% were generated in China, France, and Russia, the product’s main markets. smecta® is Ipsen’s leading Consumer HealthCare product in terms of sales.

Gastro-intestinal Conditions


An exclusive dual action against gas and bloating that favors a fast gas elimination and restores a healthy gut microbiota.

Gastro-intestinal Conditions


This liquid formulation is used in the short-term treatment of acute diarrhea, in addition to use for dietary and rehydration measures, coming in a ready to use liquid stick.

Gastro-intestinal Conditions

forlax® (Macrogol 4000)

forlax® is an oral osmotic laxative, designed and developed by Ipsen, and indicated for the treatment of constipation in both adults and children. The active substance in forlax® is Macrogol 4000, a linear polymer of polyethylene glycol (PEG) of high molecular weight.

As of 31 December 2017, forlax® was granted marketing authorizations in about 50 countries. In 2017, 49% of forlax® sales were generated in France.

Gastro-intestinal Conditions

fortrans® (Macrogol)

fortrans® is aimed at intestinal cleansing before endoscopy procedure (colonoscopy), surgery, or radiology. The active substance in fortrans® is Macrogol 4000, a linear polymer of polyethylene glycol (PEG) of high molecular weight with added electrolytes.

fortrans® is available in more than 40 countries. Russia and Poland are the two largest markets, which represent 40% of fortrans® sales.

Gastro-intestinal Conditions

eziclen® izinova® (BLI-800)

eziclen® is a next-generation osmotic laxative, indicated in adults, for cleaning the bowel before endoscopy procedure (coloscopy), surgery or radiology.

In 2009, Ipsen acquired from Braintree the exclusive manufacturing, marketing and distribution rights of the proprietary formulation BLI-800 for the European Union, the Commonwealth of Independent States (CIS), some Asian countries (including China) and some North African and South American countries. On 31 December 2017, eziclen® was marketed by Ipsen or its local partners in 20 countries.

Gastro-intestinal Conditions

Etiasa® (Mesalazine)

Etiasa® (mesalazine) is indicated in Inflammatory Bowel Diseases (Ulcerative colitis and Crohn’s Disease), for the treatment of mildl to moderate conditions and maintenance of remission.

In 2015, Ipsen renewed its exclusive agreement with Ethypharm to promote and distribute etiasa® in China.

Gastro-intestinal Conditions


An antispasmodic; sold in the Czech Republic, Estonia, Hungary, Latvia, Poland and Slovakia

Gastro-intestinal Conditions

Suppositoria Glycerini

Un laxatif, commercialisé en République Tchèque.

Other Conditions

Adenuric® (febuxostat)

Adenuric® (febuxostat) 80 mg and 120 mg (tablets) is indicated for the treatment of chronic hyperuricaemia with clinical manifestations of urate deposition (including a history or presence of tophus and/or gouty arthritis). In 2015, some indications were added for Adenuric® 120 mg for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).

The Group granted exclusive licensing rights to the Menarini Group for Adenuric® in 41 countries. In addition, Ipsen continues to promote the product in France together with Menarini.

Other Conditions

Tanakan® (EGb761®)

tanakan® contains natural substances with antioxidant and neuro-protective properties.

tanakan® is indicated for the treatment of cognitive disorders (memory or attention deficit) in the elderly. The active substance in tanakan® – EGb 761® – is a standardized extract from the leaves of Ginkgo biloba (dioecious tree in the Ginkgoaceae family) cultivated and extracted under controlled conditions.

As of 31 December 2017, tanakan® was approved in approximately 50 countries, mainly in Europe, Russia, and Asia. In 2017, 20% of tanakan® sales were generated in Russia, where the product is offered as a self-medication OTC product.

Other Conditions


An analgesic for the treatment of moderate to severe pain.

Other Conditions


Used for irritative cough, allergic cough, non productive cough with heart disease, tracheitis, bronchitis and other conditions.

Medical Devices

forlaxGO® (Macrogol 4000)

forlaxGo® is a laxative treatment for the symptomatic treatment of occasional constipation in adults and children from 8 years of age coming in a ready to use liquid stick

Food Supplements

smebiocta® (LP299V®)

smebiocta® (LP299V®), the first probiotic launched by Ipsen to maintain intestinal comfort.

In April 2016, Ipsen signed a license and supply agreement with Probi for the commercialization of its probiotic strain Lactobacillus Plantarum 299v (LP299V®). The agreement covers 18 markets, many with high growth potential, with an option to include additional countries.

In 2017, the product was launched in France, Czech Republic, Romania, and the Baltics.

In the same category